DUBLIN--(BUSINESS WIRE)--The "Global Renal Anemia Therapeutics Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
The global renal anemia therapeutics market to grow at a CAGR of 8.33% during the period 2018-2022.
The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
One trend in the market is growing focus of vendors on emerging economies. Emerging economies such as China, India, and Brazil are witnessing a growing prevalence of CKD, which is encouraging renal anemia therapeutics vendors to invest in these markets.
According to the report, one driver in the market is presence of large pool of CKD patients. The growing prevalence of CKD increases the risk of renal disease-induced ailments such as anemia, which will contribute to the demand for renal anemia therapeutics. Patients affected by health conditions such as diabetes, high blood pressure, and glomerulonephritis are susceptible to developing chronic renal ailments.
Further, the report states that one challenge in the market is side-effects of oral administration. The limitations associated with conventional oral therapies to treat anemia will reduce the demand for oral iron drugs. Earlier, oral therapies were considered the gold standard for the treatment of iron deficiency.
- AMAG Pharmaceuticals
- Daiichi Sankyo
Key Topics Covered
01. Executive Summary
02. Scope of the Report
03. Research Methodology
04. Market Landscape
05. Market Sizing
06. Five Forces Analysis
07. Market Segmentation by Application
08. Market Segmentation by Product
09. Customer Landscape
10. Regional Landscape
11. Decision Framework
12. Drivers and Challenges
13. Market Trends
14. Vendor Landscape
15. Vendor Analysis
For more information about this report visit https://www.researchandmarkets.com/research/jm8ssg/renal_anemia?w=4